0001104659-22-001565.txt : 20220105 0001104659-22-001565.hdr.sgml : 20220105 20220105171550 ACCESSION NUMBER: 0001104659-22-001565 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220104 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kruse Bo CENTRAL INDEX KEY: 0001752940 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 22512280 MAIL ADDRESS: STREET 1: C/O Y-MABS THERAPEUTICS, INC. STREET 2: 230 PARK AVENUE, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 4 1 tm221696-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-01-04 0 0001722964 Y-mAbs Therapeutics, Inc. YMAB 0001752940 Kruse Bo C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 0 1 0 0 EVP, CFO, Secretary & Treas. Common Stock 2022-01-04 4 S 0 4000 17.12 D 193077 D Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2021. /s/ Bo Kruse 2022-01-05